Press releases | UCB

UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder

UCB to present new data from its neurology portfolio at the 11th European Academy of Neurology (EAN) Congress 2025

Transparency notification FMR LLC

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activities

BIMZELX®▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis